Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.

B7-H3 B7-H4 NSCLC PD-L1 extracellular vesicle immune checkpoint inhibitors platelets prognosis soluble protein

Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
08 03 2023
Historique:
received: 27 01 2023
revised: 24 02 2023
accepted: 03 03 2023
medline: 30 3 2023
entrez: 29 3 2023
pubmed: 30 3 2023
Statut: epublish

Résumé

The treatment of non-small cell lung cancer (NSCLC) has changed dramatically with the advent of immune checkpoint inhibitors (ICIs). Despite encouraging results, their efficacy remains limited to a subgroup of patients. Circulating immune checkpoints in soluble (s) form and associated with extracellular vesicles (EVs) represent promising markers, especially in ICI-based therapeutic settings. We evaluated the prognostic role of PD-L1 and of two B7 family members (B7-H3, B7-H4), both soluble and EV-associated, in a cohort of advanced NSCLC patients treated with first- (

Identifiants

pubmed: 36980174
pii: cells12060832
doi: 10.3390/cells12060832
pmc: PMC10047289
pii:
doi:

Substances chimiques

B7-H1 Antigen 0
Immune Checkpoint Inhibitors 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Sci Rep. 2021 Oct 5;11(1):19712
pubmed: 34611279
Nat Rev Cancer. 2016 May;16(5):275-87
pubmed: 27079802
Cancer Cell Int. 2018 Aug 13;18:115
pubmed: 30123093
Br J Cancer. 2015 Apr 28;112(9):1501-9
pubmed: 25867264
Cytokine. 2022 Oct;158:155998
pubmed: 35981492
N Engl J Med. 2020 Oct 1;383(14):1328-1339
pubmed: 32997907
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Nat Rev Immunol. 2020 Apr;20(4):209-215
pubmed: 31965064
Cancer. 2008 Feb 15;112(4):863-75
pubmed: 18203207
Bull Exp Biol Med. 2021 Aug;171(4):472-474
pubmed: 34542756
Biomaterials. 2021 Feb;269:120633
pubmed: 33453634
Mol Cancer Ther. 2017 Jul;16(7):1203-1211
pubmed: 28679835
Front Oncol. 2022 Sep 14;12:983724
pubmed: 36185270
PLoS One. 2018 Jul 25;13(7):e0199719
pubmed: 30044793
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
J Clin Med. 2019 Jul 10;8(7):
pubmed: 31295929
Nat Immunol. 2001 Mar;2(3):269-74
pubmed: 11224528
Am J Epidemiol. 2003 May 15;157(10):940-3
pubmed: 12746247
Clin Lung Cancer. 2018 Sep;19(5):410-417.e1
pubmed: 29859759
Exp Mol Med. 2019 Aug 9;51(8):1-13
pubmed: 31399559
Nature. 2018 Aug;560(7718):382-386
pubmed: 30089911
Cancer. 2023 Feb 15;129(4):521-530
pubmed: 36484171
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
Clin Cancer Res. 2017 Sep 1;23(17):5202-5209
pubmed: 28539467
Clin Cancer Res. 2011 Oct 1;17(19):6118-24
pubmed: 21705455
Biomedicines. 2021 Dec 16;9(12):
pubmed: 34944745
Annu Rev Immunol. 2005;23:515-48
pubmed: 15771580
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Lung Cancer. 2017 Feb;104:1-6
pubmed: 28212990
J Exp Clin Cancer Res. 2022 Jun 2;41(1):186
pubmed: 35650597
PLoS Med. 2009 Oct;6(10):e1000166
pubmed: 19841745
Cell. 2016 Dec 1;167(6):1540-1554.e12
pubmed: 27912061
Biochem Biophys Res Commun. 2009 Nov 13;389(2):349-53
pubmed: 19723502
Arterioscler Thromb Vasc Biol. 2021 Jan;41(1):87-96
pubmed: 33028092
Hepatol Commun. 2019 Apr 22;3(7):855-866
pubmed: 31304449
Curr Protoc Stem Cell Biol. 2019 Feb;48(1):e76
pubmed: 30624011
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Eur Respir J. 2013 Mar;41(3):656-63
pubmed: 22743677
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Int J Cancer. 2014 Jun 15;134(12):2764-71
pubmed: 24013874
Front Immunol. 2018 May 04;9:847
pubmed: 29780381
Nat Commun. 2021 Dec 1;12(1):7005
pubmed: 34853305
Cancer Sci. 2018 Jan;109(1):43-53
pubmed: 29034543
J Immunother. 2007 Apr;30(3):251-60
pubmed: 17414316
Gynecol Oncol. 2014 Jul;134(1):181-189
pubmed: 24657487
Scand J Immunol. 2001 Nov;54(5):453-8
pubmed: 11696196
Immunology. 2008 Apr;123(4):538-46
pubmed: 18194267
J Clin Med. 2019 Oct 01;8(10):
pubmed: 31581482
J Thorac Oncol. 2021 Oct;16(10):1718-1732
pubmed: 34048946

Auteurs

Carlo Genova (C)

UOC Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.
Dipartimento di Medicina Interna e Specialità Mediche (DiMI), Università degli Studi di Genova, 16132 Genova, Italy.

Roberta Tasso (R)

Dipartimento di Medicina Sperimentale (DIMES), Università degli Studi di Genova, 16132 Genova, Italy.
UO Oncologia Cellulare, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.

Alessandra Rosa (A)

U.O. Epidemiologia Clinica, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.

Giovanni Rossi (G)

U.O.C. Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.
Dipartimento di Medicina, Chirurgia e Scienze Sperimentali Università di Sassari, 07100 Sassari, Italy.

Daniele Reverberi (D)

U.O. Patologia Molecolare, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.

Vincenzo Fontana (V)

U.O. Epidemiologia Clinica, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.

Silvia Marconi (S)

U.O.S. Tumori Polmonari, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.

Michela Croce (M)

U.O.C. Bioterapie, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.

Maria Giovanna Dal Bello (MG)

S.S.D. Animal Facility, IRCSS Ospedale Policlinico San Martino, 16132 Genoa, Italy.

Chiara Dellepiane (C)

U.O.C. Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.

Marco Tagliamento (M)

Dipartimento di Medicina Interna e Specialità Mediche (DiMI), Università degli Studi di Genova, 16132 Genova, Italy.

Maria Chiara Ciferri (MC)

Dipartimento di Medicina Sperimentale (DIMES), Università degli Studi di Genova, 16132 Genova, Italy.

Lodovica Zullo (L)

U.O.C. Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.

Alessandro Fedeli (A)

Dipartimento di Ingegneria Navale, Elettrica, Elettronica e delle Telecomunicazioni (DITEN), Università degli Studi di Genova, 16145 Genova, Italy.

Angela Alama (A)

U.O.S. Tumori Polmonari, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.

Katia Cortese (K)

Dipartimento di Medicina Sperimentale (DIMES), Università degli Studi di Genova, 16132 Genova, Italy.

Chiara Gentili (C)

Dipartimento di Medicina Sperimentale (DIMES), Università degli Studi di Genova, 16132 Genova, Italy.
UO Oncologia Cellulare, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.

Eugenia Cella (E)

U.O.C. Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.

Giorgia Anselmi (G)

U.O. Anatomia Patologica Ospedaliera, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.

Marco Mora (M)

U.O. Anatomia Patologica Ospedaliera, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.

Giulia Barletta (G)

U.O.C. Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.

Erika Rijavec (E)

Unità di Oncologia Medica, Dipartimento della Medicina e Chirurgia, Università dell'Insubria, ASST dei Sette Laghi, 21100 Varese, Italy.

Francesco Grossi (F)

Unità di Oncologia Medica, Dipartimento della Medicina e Chirurgia, Università dell'Insubria, ASST dei Sette Laghi, 21100 Varese, Italy.

Paolo Pronzato (P)

U.O.C. Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.

Simona Coco (S)

U.O.S. Tumori Polmonari, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH